Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.

Haowei Linda Sun Ming Yang Man-Chiu PoonAdrienne LeeK Sue RobinsonMichelle SholzbergJohn WuAlfonso IorioVictor BlanchetteManuel D CarcaoRobert J KlaassenShannon Jackson

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Switching from SHL to EHL products led to a small reduction in factor utilization, while preserving a low ABR in children and adults with haemophilia. Further patient-reported outcomes data will further elucidate the role of EHL in the haemophilia landscape.

Keyphrases

patient reported outcomes
young adults
electronic health record
single cell
type diabetes
metabolic syndrome
adipose tissue
glycemic control
weight loss
deep learning